Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志  2015, Vol. 35 Issue (12): 109-114    DOI: 10.13523/j.cb.20151217
医药生物技术专栏     
聚乙二醇化重组蛋白药物的质量控制
李星1,2, 姚文兵1, 徐晨2
1. 中国药科大学生命科学与技术学院 南京 210000;
2. 北京三元基因工程有限公司 北京 102600
Quality Control for PEGylated Recombinant Protein
LI Xing1,2, YAO Wen-bing1, XU Chen2
1. Life Science and Technology College of China Pharmaceutical University, Nanjing 210000, China;
2. Beijing Tri-Prime Gene Engineering Co Ltd, Beijing 102600, China
 全文: PDF  HTML
摘要:

重组蛋白经聚乙二醇(PEG)化修饰在优化药物代谢动力学和药效学性质的同时,使药物的结构和质量属性变得更为复杂,修饰后的重组蛋白在结构、理化性质和生物学活性等方面与未修饰的重组蛋白相比有较大差异,对其质量控制的研究必须结合品种自身独特的质量属性。现从蛋白质药物质量控制的角度,对PEG化蛋白质药物的重要质量属性的质控难点和相应检测方法进行综述,以期对工艺开发和生产上的实际工作有所帮助。

关键词: 重组蛋白聚乙二醇修饰质量控制    
Abstract:

Modified by polyethylene glycol, recombinant protein has better pharmacokinetic and pharmacodynamic properties while the structure and quality attributes become more complex. The modified recombinant protein has a big change in the structure, physical and chemical properties, and the biological activity. Therefore, it is important to consider the unique quality attributes of pegylated recombinant protein when researching the quality control. Difficulties of quality control and detection methods of important quality attributes of pegylated recombinant protein drugs are reviewed, to help future drug development and manufacturing process.

Key words: Recombinant protein    Polyethylene glycol modification    Quality control
收稿日期: 2015-07-06 出版日期: 2015-12-22
ZTFLH:  R917  
通讯作者: 姚文兵, 徐晨     E-mail: wbyao@cpu.edu.cn;xuchen@triprime.com
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  
李星
姚文兵
徐晨

引用本文:

李星, 姚文兵, 徐晨. 聚乙二醇化重组蛋白药物的质量控制[J]. 中国生物工程杂志, 2015, 35(12): 109-114.

LI Xing, YAO Wen-bing, XU Chen. Quality Control for PEGylated Recombinant Protein. China Biotechnology, 2015, 35(12): 109-114.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20151217        https://manu60.magtech.com.cn/biotech/CN/Y2015/V35/I12/109

[1] Abuchowski A, Van Es T, Palczuk N C, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol.J Biol Chem, 1977, 252(11):3578-3581.
[2] 王旭东,李晓晖,苏志国,等.蛋白药物的聚乙二醇定点修饰策略与最佳位点.中国生物工程杂志, 2010, 30(4):101-109. Wang X D, Li X H, Su Z G, et al. Site-specific PEGylation strategies and suitable modified sites of protein drugs. China Biotechnology, 2010, 30(4):101-109.
[3] World Health Organization. WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology. Switzerland:WHO Press,2013.91-92.
[4] 梁凌宇,王婉茹,郭玉婷,等. RP-HPLC法检测CN10蛋白的PEG化修饰率及含量.微生物学免疫学进展, 2015, 43(1):14-18. Liang L Y, Wang W R, Guo Y T, et al. Determination of modification rate and content of PEGylated CN10 by RP-HPLC. Progress in Microbiology and Immunology, 2015, 43(1):14-18.
[5] 李晶,王永利,杨化新,等.三硝基苯磺酸法测定聚乙二醇化重组人生长激素的平均修饰度.现代生物医学进展, 2011,11(9):1609-1612. Li J, Wang Y L, Yang H X, et al. Determination of average degree of modification of pegylated recombinant human growth hormone by trinitrobenzene sulfonic acid. Progress in Modern Biomedicine, 2011,11(9):1609-1612.
[6] Bullock J, Chowdhury S, Severdia A, et al. Comparison of results of various methods used to determine the extent of modification of methoxy polyethylene glycol 5000-modified bovine cupri-zinc superoxidedismutase. Anal Biochem, 1997, 254(2):254-262.
[7] Stocks S J, Jones A J, Ramey C W, et al. A fluorometric assay of the degree of modification of protein primary amines with polyethylene glycol. Anal Biochem, 1986,154(1):232-234.
[8] 李晶,何辉,程速远,等.荧光胺衍生化法测定3种聚乙二醇化重组人生长激素的平均修饰率.药物分析杂志,2014,34(8):1368-1373. Li J, He H, Cheng S Y, et al. A fluorometric assay to determine the average modification rate of three kinds of PEG-rhGHs. Chin J Pharm Anal, 2014,34(8):1368-1373.
[9] 李晶,梁成罡.聚乙二醇化重组人生长激素质控难点探讨.中国新药杂志,2014,23(3):271-274. Li J, Liang C G. Difficulties in quality control of PEGylated rhGH. Chinese Journal of New Drugs,2014,23(3):271-274.
[10] 李修乐.聚乙二醇化蛋白的修饰位点识别研究.泰安:山东农业大学食品科学与工程学院, 2013. Li X L. Methods for identification of conjugationsite on pegylated protein. Taian:Institute of Food Science and Engineering, Shandong Agricultural University, 2013.
[11] Monkarsh S P, Ma Y, AglioneA,et al. Positional isomers of monopegylated interferon alpha-2a:isolation, characterization, and biological activity.Anal Biochem, 1997,247(2):434-440.
[12] Yu W L, Yu C M, Wu L, et al. PEGylated recombinant human interferon-x as a long-acting antiviral agent:Structure, antiviral activity and pharmacokinetics. Antiviral Research, 2014(108):142-147.
[13] Lu X J, Gough P C, DeFelippis M R, et al. Elucidation of PEGylation site with a combined approach of In-source fragmentation and CID MS/MS. J Am Soc Mass Spectrom, 2010, 21(5):810-818.
[14] Yoo C, Suckau D, Sauerland V, et al. Toward top-down determination of PEGylation site using MALDI in-source decay MS analysis. J Am Soc Mass Spectrom,2009,20(2):326-333.
[15] 张苏,张培彪.聚乙二醇化重组人干扰素β-1a注射液中游离聚乙二醇残留量的测定.中国现代应用药学,2014,31(8):966-968. Zhang S, Zhang P B. Determination of Free PEG in PEG-rhIFN-β-1a injection. Chin J Mod Appl Pharm, 2014,31(8):966-968.
[16] 李永红,李响,韩春梅,等.高效液相色谱蒸发光散射检测法测定聚乙二醇干扰素α-2a注射液中游离聚乙二醇的含量.药物生物技术, 2014,21(4):353-354. Li Y H, Li X, Han C M, et al. Quantitation of free polyethylene glycol in PEGylated interferon alpha-2a injection by HPLC-ELSD. Pharmaceutical Biotechnology, 2014,21(4):353-354.
[17] 苑方圆,李晶,梁成罡,等.聚乙二醇(PEG)化尿酸氧化酶中游离PEG的含量测定.药物分析杂志,2014,34(3):461-464. Yuan F Y, Li J, Liang C G, et al. Determination of the content of free polyethylene glycol in PEGylated uricase. Chin J Pharm Anal, 2014,34(3):461-464.
[18] Kurfürst M M. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem, 1992, 200(2):244.
[19] Hardy E, Ramón J, Saez V, et al. Detection of PEGylated proteins in polyacrylamide gels by reverse staining withzinc and imidazole salts. Electrophoresis, 2008, 29(11):2363-2371.
[20] Fee C J, Van J M. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylatedproteins. Bioconjug Chem, 2004,15(6):1304-1313.
[21] 王军志.生物技术药物研究开发与质量控制.第2版.北京:科学出版社, 2007.71-102. Wang J Z. The Research Development and Quality Control of Biomedical. 2nd ed. Beijing:Science Press, 2007.71-102.
[22] Zheng C Y, Ma G H, Su Z G. Native PAGE eliminates the problem of PEG-SDS interaction in SDS-PAGE and provides an alternative to HPLC in characterization of protein PEGylation. Electrophoresis, 2007, 28(16):2801-2807.
[23] Möller I, Thomas A, Geyer H, et al. Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes. Rapid Communications in Mass Spectrometry, 2011,25(15):2115-2123.
[24] 吴影新,翟艳琴,雷建都,等.聚乙二醇修饰蛋白体系的SDS-聚丙烯酰胺凝胶电泳染色方法新探.化学通报,2005,72(5):459-462. Wu Y X, Zhai Y Q, Lei J D, et al. Application of three kinds of staining methods for PEGylated protein system in SDS-PAGE. Chemistry, 2005,72(5):459-462.
[25] 谭和平,王彧婕,邹燕,等.蛋白质分子质量测试方法概述.中国测试,2011, 37(2):34-37. Tan H P, Wang Y J, Zou Y, et al. Methods of molecular weight determination of proteins. China Measurement & Test, 2011,37(2):34-37.
[26] Huang L, Gough P C, Defelippis M R. Characterization of poly(ethylene glycol)and PEGylated products by LC/MS with postcolumn addition of amines. Anal Chem, 2009, 81(2):567-577.
[27] Foser S, Schacher A, Weyer K A, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a(PEGASYS). Protein Expression and Purification, 2003,30(1):78-87.
[28] Huang Y S, Wen X F, Wu Y L, et al. Engineering a pharmacologically superior form of granulocytecolony-stimulating factor by fusion with gelatin-like-protein polymer. Eur J Pharm Biopharm, 2010, 74(3):435-441.
[29] Wadhwa M, Bird C, Dougall T, et al. Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF):report of an international collaborative study. Journal of Immunological Methods, 2015,416:17-28.

[1] 刘国芳,刘晓志,高健,王志明. 宿主细胞残留蛋白质对单克隆抗体药物质量影响及其质量控制 *[J]. 中国生物工程杂志, 2019, 39(10): 105-110.
[2] 王佩, 陈凯, 高嵩. 利用CpG DNA甲基化酶M.Sss I共表达载体制备限制性内切酶Not I[J]. 中国生物工程杂志, 2017, 37(8): 51-58.
[3] 刘延娟, 李旭娟, 袁航, 刘娴, 高艳秀, 龚明, 邹竹荣. 融合酰基载体蛋白可增强大肠杆菌重组蛋白的可溶性和热稳定性[J]. 中国生物工程杂志, 2017, 37(7): 115-123.
[4] 迟胜男,李增兰,张纯,殷爽,冯翠,王祺,刘永东,苏志国. 聚乙二醇20k修饰与转铁蛋白偶联睫状神经营养因子的生物活性对比研究 *[J]. 中国生物工程杂志, 2017, 37(12): 59-66.
[5] 林优红, 程霞英, 严依雯, 梁宗锁, 杨宗岐. 衣藻叶绿体表达重组蛋白及表达优化策略[J]. 中国生物工程杂志, 2017, 37(10): 118-125.
[6] 杨思源, 潘敬梅, 王硕, 邓开轩, 邓强, 黄新河, 李学如. 化脓性链球菌溶血素O活性结构重组蛋白的制备[J]. 中国生物工程杂志, 2016, 36(6): 51-56.
[7] 王佃亮. 细胞药物的标准及质量控制——细胞药物连载之四[J]. 中国生物工程杂志, 2016, 36(10): 115-121.
[8] 邱丽娟, 赵玉娇, 李多, 黄新伟, 王晓丹, 席珏敏, 潘玥, 陈俊英, 孙强明. 登革病毒四型联合重组包膜蛋白III区的表达和免疫原性鉴定[J]. 中国生物工程杂志, 2016, 36(1): 1-6.
[9] 李多, 杨丽娟, 赵玉娇, 潘玥, 陈俊英, 付娟娟, 黄新伟, 邱丽娟, 孙强明. 研究报告重组Ⅱ型登革病毒NS1的表达及其免疫原性的研究[J]. 中国生物工程杂志, 2014, 34(9): 4-8.
[10] 王兰, 夏懋, 高凯. 抗体偶联药物的研究进展与质量控制[J]. 中国生物工程杂志, 2014, 34(4): 85-94.
[11] 王靖瑶, 王天女, 卢磊, 张帅, 赵敏. 大肠杆菌I型分泌表达系统研究进展及提高蛋白表达量的策略[J]. 中国生物工程杂志, 2014, 34(06): 98-104.
[12] 孙少飞, 汪蓓蕾, 袁婷, 张斌, 张欣, 郭刚, 张瑞. 重组蛋白TAT-NLS-Nkx6.2在大肠杆菌的表达纯化及活性测定[J]. 中国生物工程杂志, 2013, 33(9): 24-30.
[13] 王晶, 吴陆生, 陈小佳, 董濠鋆, 沈巍, 张敏仪, 洪岸. 重组蛋白NtA-PACAP在大肠杆菌中的表达纯化及活性测定[J]. 中国生物工程杂志, 2013, 33(3): 28-33.
[14] 石磊, 唐莉莉, 马兴元, 王天文, 马飞, 王平. 利用类弹性蛋白可逆相变和内含肽自切割功能高效制备TmSm抗肿瘤蛋白[J]. 中国生物工程杂志, 2013, 33(10): 89-95.
[15] 陈爱春, 彭伟, 汪生鹏. 亲和标签在重组蛋白表达与纯化中的应用[J]. 中国生物工程杂志, 2012, 32(12): 93-103.